Mr. Kanyon has extensive pharmaceutical and medical device business experience across the life-science value chain. Before being appointed CEO of AusCann, Mr. Kanyon held a broad range of executive positions at Teva Pharmaceuticals (NYSE:TEVA, FY18 revenues of over US$18 billion), including key leadership roles in Strategic Portfolio Management, Innovative Medicine Brand Marketing, Generics Pharmaceutical Manufacturing, Medical Device Regulatory Affairs and Quality Assurance. Prior to his tenure at Teva, Mr. Kanyon worked within an agricultural research organization, led R&D projects for startup companies, and repeatedly transitioned academic research into robust class III implantable medical devices.
Mr. Kanyon has successfully launched innovative medicines globally, providing more patients with access to cost-effective, high-quality, life-changing treatment options. His experience covers a comprehensive range of healthcare technologies and commercial strategies: from capsules and inhalers to innovative biologics and digital health solutions.
Mr. Kanyon holds a B.Sc.(Agr.) from The Hebrew University Of Jerusalem, Israel, an MBA from IE Business School in Spain and Postgraduate training with Mckinsey & Co. He holds a fellowship with the College of Physicians of Philadelphia and participates in advisory boards with several technological incubators, such as the leading US accelerator Dreamit Ventures. He has lived and worked in North America, Europe, Asia, and the Middle East.
Cheryl was the former Attorney-General for Western Australia and Minister for the Environment. Cheryl was most recently Executive General Manager for External Affairs, Government Relations and Approvals at Hancock Prospecting-a company associated with one of Australia’s wealthiest individuals.
Cheryl has extensive experience of successful negotiations to ensure that critical primary agreements and government approvals are obtained in a timely fashion. Such agreements and approvals include the Roy Hill Rail State Agreement and the Special Railway Licence; Port Lease and Licence; Native Title Agreements; Environmental Approvals, State and Federal; and many other critical approvals for Hancock Prospecting Pty Ltd and Roy Hill Iron Ore and Infrastructure.
Dr. Bonn-Miller is Global Clinical Scientific Director of Spectrum Therapeutics, the medical division of Canopy Growth specialised in the development and commercialisation of validated cannabis medicines. Dr. Bonn-Miller is a world-renowned researcher and pharmaceutical executive, bringing over 18 years of extensive clinical research and development expertise in cannabinoid-products for medical use. He has received funding for 27 research grants, has published 140 peer reviewed academic papers and has led or contributed to 19 clinical trials. Prior to
Canopy Growth, Dr. Bonn-Miller was Director of Cannabinoid Research for Zynerba Pharmaceuticals, a leading transdermal cannabinoid pharmaceutical company.
Bruce is a highly experienced senior executive and independent company director with a background in the life sciences industry focussed on finance, operations, governance, business and investment management, and strategic planning.
In addition to Auscann, Bruce is a non-executive director of Adherium Limited, an ASX listed digital health technology company and he is a Special Adviser to BioScience Managers Pty Ltd, an international healthcare investment firm that finances and enables innovative science and technology with the potential to transform healthcare.
Bruce previously served as the Chief Financial Officer, Director of Operations and Director of Strategic Projects with the Telethon Kids Institute in Western Australia. Prior to joining the Institute, Bruce was based in London as an Assistant Director at Rothschild Asset Management in the Bioscience Unit, a life sciences private equity group investing in early stage biotechnology, healthcare and agribusiness companies. He co-founded two Institute spin-outs including publicly listed drug discovery company, Phylogica Limited, and has held a number of other non-executive director positions in biotechnology and not-for-profit healthcare organisations.
He is a Fellow of the Institute of Chartered Accountants Australia and New Zealand, holds a Bachelor of Commerce degree from the University of Western Australia, and is a graduate member of the Australian Institute of Company Directors.
Mr Mews is an experienced non-executive director with over 20 years in the financial services sector, having held senior positions in finance, corporate secretarial and compliance in listed and unlisted companies. Mr Mews is currently the Chief Financial Officer and Company Secretary of Merchant Group Pty Ltd, a Perth based financial services firm that provides funds management and corporate finance services, with investment experience both in Australia and internationally in the medical cannabis sector. Prior to Merchant Group, he was the Chief Financial Officer and Company Secretary of listed biotech Company Polynovo Limited (ASX:PNV), and is currently Company Secretary and Non-Executive Director of VPCL Limited (ASX:VPC). Mr Mews holds a Bachelor of Business majoring in Accounting and is a Certified Practising Accountant, a Chartered Company Secretary and member of the Governance Institute of Australia.
Susan has over 20 years’ experience in the corporate finance industry. She is founder and managing director of consulting firm Hunter Corporate Pty Ltd, which specialises in the provision of corporate governance and company secretarial advice to ASX listed companies, and has previously held senior management roles at Ernst & Young, PricewaterhouseCoopers and Bankwest, both in Perth and Sydney.
Susan holds a Bachelor of Commerce, is a Member of the Australian Institute of Chartered Accountants, a Fellow of the Financial Services Institute of Australasia, a Graduate Member of the Australian Institute of Company Directors and an Associate of the Governance Institute of Australia Ltd.
She is currently company secretary for several ASX listed companies.
Quentin Megson has over 25 years’ experience in the finance and management sector and holds a Bachelor of Commerce and is a Member of the Australian Institute of Chartered Accountants. He started as a Tax Advisory Manager with a major accounting firm before moving to a medium tier accounting firm as a Partner. He then chose to move into commerce as the CFO and Company Secretary of an ASX listed company operating in the forestry/ agriculture industry and then moved into an operational role as General Manager of Operations & Corporate Services. Quentin has also held non-executive director roles within several companies.
Melinda holds a doctorate in biochemistry with postdoctoral research experience in molecular biology. She has over ten years’ experience, and has held several senior roles, in research and development management, with a focus on governance frameworks and operational processes, including the development of bespoke research management systems, contractual frameworks and risk assessment of research activities, including clinical trials.
Sheena has more than 16 years’ experience in pharmaceutical manufacturing, with over 8 years in quality management. She has worked in both sterile & non-sterile pharmaceutical manufacturing with extensive experience in Good Manufacturing Practice (GMP) under the regulations of the ICH, PIC/S and audited by TGA, FDA, WHO & SAHPRA.
Sheena has also held Quality Assurance roles for both a Clinical Research Organisation & Bioanalytical Laboratory under Good Clinical Practice (GCP) guidelines.
Her skills are Quality Control, Corrective and Preventive Action (CAPA), Good Laboratory Practice (GLP), GMP, GCP and Quality Assurance.